Dronedarone in Pacemaker Patients With Paroxysmal Atrial Fibrillation (DROPPAF)

NCT01070667 Phase 4 UNKNOWN

The purpose of this study is to accurately investigate the efficacy of dronedarone in maintaining sinus rhythm and decreasing AFB in patients with paroxysmal atrial fibrillation as compared with placebo. This has never previously been performed using pacemaker Holter monitoring which provides detailed information of atrial arrhythmia patterns the entire study period. Additionally detailed patient symptom self assessment and questionnaires will be collected. The study design will be double blinded crossover with each phase lasting 3 months.

Details

Lead sponsor	Eastbourne General Hospital
Phase	Phase 4
Status	UNKNOWN
Enrolment	50
Start date	2010-03
Completion	2010-03

Conditions

• Paroxysmal Atrial Fibrillation

Interventions

• Dronedarone
• Placebo

Primary outcomes

• To accurately assess, by the use of long term beat to beat pacemaker Holter monitoring, the effect of of dronedarone upon AF burden. — 3 months

Countries

United Kingdom